Strides Pharma Science Ltd Faces Mildly Bearish Momentum Amid Mixed Technical Signals

Technical Trend Overview

Recent analysis reveals that Strides Pharma Science Ltd’s technical trend has shifted from a neutral sideways pattern to a mildly bearish stance. This change is reflected across multiple timeframes, with weekly and monthly indicators predominantly signalling caution. The stock closed at ₹844.40 on 4 Mar 2026, down 0.78% from the previous close of ₹851.05, with intraday prices ranging between ₹790.00 and ₹846.90. This movement comes against a 52-week high of ₹1,024.90 and a low of ₹551.00, indicating the stock remains well below its peak but comfortably above its annual low.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator, a key momentum gauge, presents a mildly bearish signal on both weekly and monthly charts. This suggests that the stock’s upward momentum is weakening, with the MACD line likely below the signal line, indicating potential downward pressure. The bearish MACD aligns with the recent price decline and the shift in trend, signalling that the stock may face resistance in sustaining gains in the near term.

RSI Signals and Overbought/Oversold Conditions

The Relative Strength Index (RSI) offers a mixed picture. On the weekly timeframe, the RSI remains neutral with no clear signal, hovering around mid-range levels that neither indicate overbought nor oversold conditions. However, the monthly RSI has turned bearish, suggesting that longer-term momentum is weakening and the stock could be entering a phase of correction or consolidation. This divergence between weekly and monthly RSI readings highlights the importance of monitoring multiple timeframes for a comprehensive view.

Moving Averages and Bollinger Bands

Daily moving averages provide a mildly bullish signal, indicating that short-term price action retains some upward bias. This is likely due to the stock price trading above key short-term averages such as the 20-day and 50-day moving averages. Conversely, Bollinger Bands show a bearish stance on the weekly chart, with the price possibly testing or moving below the lower band, signalling increased volatility and potential downside risk. The monthly Bollinger Bands, however, remain mildly bullish, suggesting that over a longer horizon, the stock may still have some upside potential.

KST and Dow Theory Assessments

The Know Sure Thing (KST) indicator, which aggregates multiple momentum cycles, signals bearishness on the weekly chart and mildly bearish conditions on the monthly chart. This reinforces the view that momentum is waning, particularly in the short to medium term. Meanwhile, Dow Theory analysis presents a nuanced picture: weekly data suggests a mildly bearish trend, whereas monthly data indicates a mildly bullish outlook. This divergence underscores the stock’s current technical uncertainty and the need for investors to weigh short-term risks against longer-term opportunities.

Volume and On-Balance Volume (OBV) Trends

Volume-based indicators such as On-Balance Volume (OBV) show no clear trend on either weekly or monthly charts. The absence of a definitive volume trend suggests that market participation is not strongly favouring either buyers or sellers at present. This lack of conviction in volume may contribute to the sideways to mildly bearish price action observed recently.

Comparative Performance Against Sensex

Examining Strides Pharma’s returns relative to the Sensex provides additional context. Over the past week, the stock declined by 3.39%, slightly outperforming the Sensex’s 3.67% drop. Over one month, Strides Pharma gained 1.05%, contrasting with the Sensex’s 1.75% loss. Year-to-date, the stock is down 6.42%, marginally worse than the Sensex’s 5.85% decline. However, over longer horizons, Strides Pharma has significantly outperformed the benchmark, delivering a 35.76% return over one year compared to the Sensex’s 9.62%, and an impressive 497.47% over three years versus the Sensex’s 36.21%. This long-term outperformance highlights the company’s growth credentials despite recent technical headwinds.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Strides Pharma a Mojo Score of 43.0, categorising it as a Sell with a recent downgrade from Hold on 16 Feb 2026. The Market Cap Grade stands at 3, reflecting a mid-tier valuation relative to peers. This downgrade aligns with the technical deterioration observed and suggests that analysts are cautious about the stock’s near-term prospects. Investors should consider this rating in conjunction with technical signals and fundamental factors before making decisions.

Investor Takeaway and Outlook

Strides Pharma Science Ltd currently exhibits a complex technical profile with mildly bearish momentum dominating weekly and monthly charts, while daily moving averages offer some short-term bullish support. The mixed signals from MACD, RSI, Bollinger Bands, and KST indicators suggest that the stock is in a consolidation phase with a bias towards downside risk in the near term. Investors should remain cautious and monitor key support levels around ₹790 and resistance near ₹850 to ₹860.

Long-term investors may find comfort in the company’s strong historical returns and sector positioning within Pharmaceuticals & Biotechnology, but the recent downgrade to a Sell rating by MarketsMOJO and the technical deterioration warrant a prudent approach. Those holding the stock should consider re-evaluating their positions in light of these developments, while prospective buyers might wait for clearer bullish confirmation before committing capital.

Overall, Strides Pharma’s technical momentum shift underscores the importance of integrating multiple indicators and timeframes to form a balanced view. The stock’s performance relative to the Sensex and its long-term growth trajectory remain positive, but near-term caution is advised given the prevailing mildly bearish technical environment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →